Stocks Bristol-Myers Squibb Co

More

  • U.S. stock futures were lower this morning, ahead of the prospect for greater volatility and volume on the final Friday of the year for quadruple witching.

  • LONDON, Dec 16- Bristol-Myers Squibb's closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain's cost watchdog. However, the head of Britain's leading cancer research center said companies needed to do more to bring down the cost of such...

  • LONDON, Dec 16- Bristol-Myers Squibb's closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain's cost watchdog. In draft guidance issued on Wednesday, the National Institute for Health and Care Excellence said using Opdivo in non-small...

  • The "Fast Money" traders give their final trades of the day.

  • FRANKFURT, Dec 9- European and U.S. drug regulators are looking into whether a defective blood clotting test device affected a trial involving Bayer's top-selling anti-clotting drug Xarelto, hitting the German drugmaker's shares. "Due to the defect it is now thought that the INR device may have impacted the clotting results in some patients in the warfarin...

  • BERLIN, Dec 9- European and U.S. drug regulators are looking into whether a defective blood-clotting test device affected a trial involving Bayer's blockbuster anti-blood clotting drug Xarelto, hitting the German drugmaker's shares. Bayer and Duke University's Clinical Research Institute, which conducted some of the trial work and which used the device in...

  • LONDON, Dec 4- The cost of cancer drugs varies substantially across Europe, experts said on Friday in a new analysis that is likely to fuel debate about the rising cost of modern medicines. But there are also wide gaps in Europe, according to Wim van Harten of the Netherlands Cancer Institute and colleagues, writing in the journal Lancet Oncology.

  • Nov 30- The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer. The FDA said it approved the treatment, Empliciti, to be used in multiple myeloma patients in combination with Celgene Corp's Revlimid and common anti-inflammatory drug dexamethasone.

  • Nov 27- Bristol-Myers Squibb Co said the U.S. Food and Drug Administration declined to approve its immuno-oncology drug, Opdivo, for its expanded use to treat an additional type of advanced skin cancer. The FDA approved Opdivo as a single agent for the treatment of patients with BRAF V600 wild-type melanoma earlier this week, but on Friday declined the approval...

  • Nov 23- U.S. Food and Drug Administration approved Bristol-Myers Squibb Co's drug, Opdivo, for treatment of advanced renal cell carcinoma, a type of kidney cancer. The drug is already approved to treat advanced melanoma and a common form of lung cancer. Opdivo belongs to a highly promising new class of medicines called PD-1 inhibitors that block a mechanism used...

  • Nov 17- The American Medical Association on Tuesday called for a ban on advertising prescription drugs and medical devices directly to consumers, saying the ads drive patients to demand expensive treatments over less costly ones that are also effective. The United States and New Zealand are the only two countries that allow direct-to-consumer advertising...

  • *Q3 profit $1.23/ shr vs. est. Nov 5- Celgene Corp posted its smallest revenue growth in five quarters due to slower sales of its two key cancer drugs. Growing sales of expensive new cancer drugs and other treatments helped top U.S. drugmakers such as Pfizer Inc, Merck& Co and Bristol-Myers Squibb Co post stronger-than-expected quarterly profits last month.

  • LONDON, Nov 5- AstraZeneca lifted its full-year forecast for revenue and earnings on Thursday as Chief Executive Pascal Soriot said the group was showing resilience, despite eroding sales of some of its top-selling medicines. "Looking ahead, however, the continued performance of our growth platforms and upcoming launches will combine with our increasing...

  • Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Mad Money Lightning Round

    Jim Cramer quickly gives his take to caller favorite stocks at lightning speed, including this play on commodities.

  • Trader on the floor of the New York Stock Exchange.

    Earnings news, especially from Apple, could stir up a market that's waiting for the Fed.

  • A trader signals an offer in a Treasury note options pit at the CME Group in Chicago.

    U.S. sovereign bonds traded higher on Monday ahead of the Federal Reserve's two-day policy meeting this week and a raft of major corporate earnings.

  • The "Halftime Report" traders give their top trades of the show.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stock index futures indicated a flat to mildly lower open as traders prepare for the Fed's two-day meeting this week and a slew of earnings.

  • Jim Cramer on the set of Mad Money

    “Mad Money” host Jim Cramer takes the time to reveal the stocks that are running away from the competition.